Intercept: Identifying and Managing Cancer Treatment Cardiotoxicities in Patients Undergoing Therapy. What is Cardiotoxicity? An Overview

April 29, 2021

A curriculum designed to engage clinicians in an educational initiative aimed at improving the overall care for cancer patients at risk for cardiotoxicity associated with their treatment. This program is part 1 of 4 live webinars provided by expert clinical faculty. 

Learning Objectives

  • Review recent data on cytotoxic chemotherapies, targeted therapies, and immunotherapies known to cause cardiotoxicity in cancer patients
  • Apply evidence-based approaches to identify and assess patients at risk for cardiotoxicity
  • Discuss the use of clinical tools, imaging, and other tests to evaluate patients at risk for cardiotoxicity before, during, and after cancer treatment
  • Discuss guidelines for the management of cancer patients at risk for cardiotoxicity
  • Employ multidisciplinary strategies to mitigate the risk for cardiotoxicity in cancer patients
Course summary
Available credit: 
  • 1.00 ABIM MOC
  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)™
Registration Opens: 
04/29/2021
Registration Expires: 
04/28/2022
Activity Starts: 
04/29/2021 - 4:00pm EDT
Activity Ends: 
04/29/2021 - 5:00pm EDT
Add to calendar: 
Rating: 
0
Durham, NC 27710
United States

Available Credit

  • 1.00 ABIM MOC
  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)™
Please login or register to take this course.